Epidemiology
A malignant blood (hematologic) cancer — a lymphoma, not a sarcoma — that arises in bone; it is an uncommon extranodal lymphoma that can involve one or several bone sites (most often a diffuse large B-cell lymphoma). It may respond better to hematologic treatment than to wide resections, so confirming the subtype completely changes the plan.
Basic features
It can cause pain, a mass, or a fracture, and sometimes the X-ray underestimates the extent within the bone marrow, which MRI does show. The subtype and stage are defined with a biopsy and staging workup directed by hematology.
Usual treatment
Treatment is directed by hematology, focused on the subtype and stage (usually chemoimmunotherapy, with radiotherapy in selected situations). Surgery is reserved for the biopsy or for mechanical stabilization, not for a sarcoma-type wide resection. Before chemotherapy starts it is worth discussing fertility preservation with the team, because some of these treatments can affect it and the options have to be raised beforehand.
Outcomes and prognosis
The prognosis depends on the hematologic subtype, the stage, and the response to systemic treatment. Many localized bone lymphomas respond well to modern therapy; follow-up is defined by hematology.